Pioneering Medical Innovations
The allay Hydrogel Cap received an Innovative Technology contract from Vizient, the nation’s largest provider-driven healthcare performance improvement company.
The first peer-reviewed clinical data on the allay Hydrogel Cap was published in Plastic and Reconstructive Surgery, Global Open, in a paper on early clinical experience treating and preventing symptomatic neuroma.
Tulavi announced an expanded indication for the allay Hydrogel Cap covering patients weighing 25 kg (55 lbs) and above, extending its reach to smaller patients at risk of symptomatic neuromas.
Tulavi was selected to exhibit the allay Hydrogel Cap at the Vizient Innovative Technology Exchange in Las Vegas.
Tulavi partnered with Veterans Healthcare Supply Solutions to distribute the allay Hydrogel Cap to VA hospitals and Military Treatment Facilities nationwide.
Veteran medtech executive Raymond W. Cohen was appointed Vice Chairman of Tulavi Therapeutics’ Board of Directors.